New long‑term clinical data show that TREMFYA® (guselkumab), an IL‑23 inhibitor, is the first treatment of its kind to demonstrate durable protection against joint damage in patients with active psoriatic arthritis (PsA). According to Johnson & Johnson, TREMFYA® significantly inhibited progression of joint structural damage in the Phase 3b APEX study, outperforming placebo by more than two‑and‑a‑half times.
